GT
GMAB icon

Glenmede Trust’s Genmab GMAB Stock Holding History

Glenmede Trust’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,771
Closed -$208K – 1525
2026
Q1 		$208K Sell
7,771
-7,072
-48% -$212K ﹤0.01% 1294
2025
Q4 		$457K Buy
+14,843
New +$463K ﹤0.01% 974
2025
Q1 		$258K Buy
13,193
+2,183
+20% +$45.8K ﹤0.01% 1135
2024
Q4 		$230K Buy
+11,010
New +$242K ﹤0.01% 1194
2024
Q3 		– Sell
-8,698
Closed -$219K – 1405
2024
Q2 		$219K Buy
+8,698
New +$247K ﹤0.01% 1162
2020
Q4 		– Sell
-15,958
Closed -$583K – 1628
2020
Q3 		$583K Buy
15,958
+14,168
+792% +$512K ﹤0.01% 744
2020
Q2 		$60K Buy
1,790
+740
+70% +$20.2K ﹤0.01% 1274
2020
Q1 		$23K Hold
1,050
– – ﹤0.01% 2017
2019
Q4 		$23K Buy
1,050
+60
+6% +$1.31K ﹤0.01% 2017
2019
Q3 		$20K Buy
+990
New +$19.5K ﹤0.01% 2038

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Glenmede Trust's GMAB Position: Q2 2026 in Review

Glenmede Trust sold out of Genmab (GMAB) in Q2 2026, closing a stake of 7,771 shares — an estimated $208K sold.

Glenmede Trust first reported a position in GMAB in Q3 2019 and held it in 10 quarters. The position peaked at $583K in Q3 2020. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Glenmede Trust reported no remaining Genmab position as of Q2 2026 after selling out during the quarter.
  • Glenmede Trust sold 7,771 Genmab shares in Q2 2026, an estimated $208K.
  • Glenmede Trust first reported a position in Genmab in Q3 2019 and held it in 10 quarters.
  • Glenmede Trust's Genmab position peaked at $583K in Q3 2020.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.